Analysis of Patients with 1988 FIGO Stage-II Endometrial Cancer

Ureyen I., Turan T., Kimyon G., Karalok A., Tasci T., Boran N., ...More

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.24, no.4, pp.239-246, 2014 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 4
  • Publication Date: 2014
  • Doi Number: 10.4999/uhod.14424
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.239-246
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No


Management of stage II endometrial cancer still has many controversies. We evaluated patients with stage II (FIGO 1988) endometrial cancer operated in our clinic in terms of treatment modalities, surgico-pathological factors, recurrence rates and patterns. Fifty-three patients with 1988 FIGO stage II endometrial cancer who underwent staging surgery between January 1993 and December 2012 were included in this study. The mean age of the patients was 57 years. Cervical invasion couldn't be detected in the preoperative pelvic examination in 47 patients (88.7%). Thirty-eight patients received simple hysterectomy (SH) and 15 patients had radical hysterectomy (RH). All patients received pelvic and paraaortic lymphadenectomy. Forty-two patients took adjuvant radiotherapy. The median follow-up time of the patient population was 39 months (range 1-139 months). Recurrence was observed in four patients. There was no statistically significant difference between the RH and SH groups in terms of recurrence (p= 0.53). Advanced age, deep myometrial invasion and the lower number of harvested lymph nodes were associated with recurrence. Systemic adjuvant therapy may be involved in the first-line treatment plan in order to prevent distant failures, since they continue to be responsible for the most of the recurrences and mortality despite radical surgeries and different protocols of adjuvant radiotherapy.